Horizon Therapeutics Public Company Stock News

The U.S. Food and Drug Administration ((FDA)) granted priority review to Horizon Therapeutics'' (HZNP) biologics license application to expand the label for Krystexxa plus…

Major companies in the musculoskeletal disorders drugs market include Sanofi S. A, Pfizer Inc. , Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc. Major companies in the musculoskeletal disorders drugs market include Sanofi S. A, Pfizer Inc. , Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc.

Horizon Therapeutics (NASDAQ: HZNP) shares jumped 6.5% on March 1, after the biopharmaceutical company delivered stronger-than-expected fourth-quarter results. The post Horizon Therapeutics Delivers Upbeat Results in Q4; Shares Up 6.5% appeared first on Smarter Analyst .

Shares of Horizon Therapeutics (HZNP) are trading higher in the premarket session after its Q4 2021 results beat on the top and bottom lines and it issued 2022 guidance.

Horizon Therapeutics plc''s (NASDAQ: HZNP ) Q4 sales increased 36% Y/Y to $1.014 billion , beating the consensus of $995.87 million. The adjusted gross profit declined slightly from 87.1% to 86.5%, with an adjusted EBITDA of $416.0 million, including $36.2 million of upfront and milestone payments primarily related to the collaboration agreement with Alpine. The Company reported an adjusted EPS of $1.41, up … Full story available on Benzinga.com

Discussions of 2019 items and year-to-year comparisons between 2020 and 2019 that are not included in this Annual Report on Form 10- K can be found in "Management''s Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of our Annual Report on Form 10- K for the fiscal year ended December 31, 2020, filed with the Securities and… The post HORIZON THERAPEUTICS PUBLIC LTD CO – 10-K – Management''s Discussion and Analysis of Financial Condition and Results of Operations appeared first on InsuranceNewsNet .

Horizon Therapeutics PLC (HZNP) CEO Tim Walbert on Q4 2021 Results - Earnings Call Transcript

Horizon Therapeutics press release (HZNP): Q4 Non-GAAP EPS of $1.41 beats by $0.06.Revenue of $1.01B (+35.5% Y/Y) beats by $14.1M.Fourth-quarter 2021 adjusted EBITDA was $416.0…

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.02% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open.Consensus EPS estimate is $1.35 (+5.5% Y/Y)

Horizon Therapeutics Public Limited Company (HZNP) stock has been hot recently, gaining 8.0% over the past month.

Horizon Therapeutics plc (NASDAQ: HZNP ) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD) . The data will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society. NMOSD is a neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain, and … Full story available on Benzinga.com